莫德纳通过BARDA的快速反应伙伴关系车辆联盟获得项目奖，以加快基于信使核糖核酸的大流行性流感疫苗的开发-动脉网

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine

BioSpace 等信源发布 2024-07-02 21:32



可切换为仅中文







CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

马萨诸塞州剑桥/ACCESSWIRE/2024年7月2日/Moderna，Inc.（纳斯达克：MRNA）今天宣布通过快速反应伙伴关系工具（RRPV）获得1.76亿美元的项目奖，以加速基于MRNA的大流行性流感疫苗的开发。RRPV是由生物医学高级研究与发展局（BARDA）资助的财团，该局是美国战略准备与应对管理局（ASPR）的一部分。

Department of Health and Human Services (HHS)..

卫生与公众服务部（HHS）。。

The project award will support late-stage development for an mRNA-based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus. This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population.

该项目奖将支持基于mRNA的疫苗的后期开发，以获得针对H5流感病毒的大流行前疫苗的许可。。

The agreement also includes additional options to prepare and accelerate aresponse to future public health threats..

该协议还包括准备和加速应对未来公共卫生威胁的其他选择。。

'mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We are pleased to continue our collaboration with BARDA to expedite our development efforts for mRNA-based pandemic influenza vaccines and support the global public health community in preparedness against potential outbreaks.'.

Moderna首席执行官Stéphane Bancel说：“正如新型冠状病毒疫情期间所证明的那样，mRNA疫苗技术在应对传染病爆发方面具有功效、开发速度、生产可扩展性和可靠性等优势。”我们很高兴继续与BARDA合作，加快基于mRNA的大流行性流感疫苗的开发工作，并支持全球公共卫生界防范潜在疫情。”。

In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of investigational pandemic influenza vaccine (mRNA-1018) in healthy adults 18 years of age and older. The study includes vaccine candidates against H5 and H7 avian influenza viruses. Results from the study are expected in 2024 and will inform Phase 3 development plans..

2023年，Moderna启动了一项1/2期研究，以在18岁及以上的健康成年人中产生研究性大流行性流感疫苗（mRNA-1018）的安全性和免疫原性数据。该研究包括针对H5和H7禽流感病毒的候选疫苗。研究结果预计将于2024年公布，并将为第三阶段发展计划提供依据。。

This project is being funded with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction (OT) number: 75A50123D00005.

该项目由卫生与公众服务部（HHS）的联邦资金资助；战略准备和应对管理局（ASPR）；生物医学高级研究与发展局（BARDA），其他交易（OT）编号：75A50123D00005。

About Moderna

关于Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines..

Moderna是mRNA医学领域的领导者。通过mRNA技术的进步，Moderna正在重新想象药物的制造方式，并改变我们如何为每个人治疗和预防疾病。通过十多年来在科学、技术和健康的交叉点工作，该公司以前所未有的速度和效率开发了药物，包括最早和最有效的新型冠状病毒疫苗之一。。

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines.

Moderna的mRNA平台为传染病、免疫肿瘤学、罕见病和自身免疫性疾病的治疗和疫苗的开发提供了支持。凭借独特的文化和由Moderna价值观和心态驱动的全球团队，以负责任的方式改变人类健康的未来，Moderna努力通过mRNA药物为人们带来尽可能大的影响。

For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn..

有关Moderna的更多信息，请访问modernatx.com，并通过X（以前的Twitter）、Facebook、Instagram、YouTube和LinkedIn与我们联系。。

Moderna Forward-Looking Statements

Moderna前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the funding of $176 million from BARDA to support late-stage development for an mRNA-based influenza vaccine; the advantages of Moderna's mRNA platform for vaccine development; the timing for potential clinical study results from Moderna's pandemic influenza vaccine candidate; and the risk to humans of infection from avian influenza.

本新闻稿包含1995年《私人证券诉讼改革法案》修订版所指的前瞻性声明，包括以下声明：BARDA资助1.76亿美元，以支持基于mRNA的流感疫苗的后期开发；Moderna mRNA平台在疫苗开发中的优势；Moderna大流行性流感候选疫苗潜在临床研究结果的时机；以及人类感染禽流感的风险。

The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

本新闻稿中的前瞻性声明既不是承诺也不是保证，您不应过度依赖这些前瞻性声明，因为它们涉及已知和未知的风险、不确定性和其他因素，其中许多因素超出了Moderna的控制范围，可能导致实际结果与这些前瞻性声明所表达或暗示的结果存在重大差异。

These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.

这些风险、不确定性和其他因素包括Moderna在截至2023年12月31日的财政年度10-K表年度报告以及Moderna随后向美国证券交易委员会提交的文件中“风险因素”标题下描述的风险和不确定性，这些文件可在美国证券交易委员会的网站www.SEC.gov上查阅。

Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release..

除法律要求外，如果出现新信息、未来发展或其他情况，摩德纳不打算或不负责更新或修改本新闻稿中包含的任何前瞻性声明。这些前瞻性声明基于Moderna目前的期望，仅在本新闻稿发布之日发表。。

Moderna Contacts

现代接触

Media:

媒体：

Chris Ridley

Global Head of Media

全球媒体主管

+1 617-800-3651

Chris.Ridley@modernatx.com

Investors:

投资者：